TRVI Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 1.66%, SMA50 11.71%, SMA200 60.24%). The stock’s 14-day RSI is 56.49 (neutral), while the ATR of 0.76 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -9.59% below its high and over 274.77% above its low. Average 10-day trading volume of 2.24 million shares is slightly above the 3-month average of 1.86 million, indicating heightened recent market interest.

Trevi Therapeutics, Inc. has 121.78 million shares outstanding. The public float is 90.63 million shares, elevated short interest at 11.12% of float. This equals 11.68 million shares. The short ratio is 6.36 days. Institutional investors hold 71.96% of the float. Insiders own 1.05%. New Enterprise Associates 16, L.P. holds 10.42 million shares, NEA 16 GP, LLC has 10.42 million shares and BASKETT FOREST has 10.42 million shares.

Trevi Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.33. This means the shares are trading above this model’s fair value.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) closed at $12.74 USD, losing -$0.27 (-2.08%) from the previous close of $13.01. The stock is currently mid-range between its 52-week high and low $3.47 and $14.39. With a market capitalization of about $1.63 billion, Trevi Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.83). Key stats such as the average daily volume over the past year has been around 2.27 million shares, volume is running light vs its 52-week average. Headquartered in New Haven, CT, Trevi Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jennifer L. Good, the company employs approximately 31 people and listed since May 07, 2019. Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions.

Trevi Therapeutics, Inc. generated EPS of -$0.37 over the past year. Five-year average earnings growth is 27.09%. Wall Street analysts project EPS growth of -9.61% annually over the next five years. The latest quarter delivered EPS of -$0.08. The next quarter is forecast at -$0.10. Next year's EPS is expected at -$33.15. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 15 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $29.00 to $12.50. The high target offers 122.91% upside. The low target suggests -3.92% downside. The mean target is $20.91. This offers 60.72% upside. Trevi Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -20.0%. The prior quarter beat by -10.0%. Over the last six quarters, Apple has recorded several small beats. These include 9.09% in August 08, 2024.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares are up 215.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Trevi Therapeutics, Inc. trading at a premium to the broader market with a P/E of -40.26. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.09, suggesting 23.67% upside. Our AI forecast model points to short-term strength (5.92% over two weeks), a medium-term rise (95.93% over three months), and a longer-term gain (171.48% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Trevi Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.92%, with price expected at $13.78 by January 02, 2026, within a range of $12.99 to $14.61 3-Month Outlook: Projected rise of 95.93%, reaching $25.49 by March 19, 2026, with a range of $25.32 to $25.67. 1-Year Outlook: Projected gain of 171.48%, with price at $35.32 by December 18, 2026, within a range of $37.40 to $38.46.

Trevi Therapeutics, Inc. trades at a P/E ratio of -40.26, slightly below the S&P 500 average, with a price-to-sales ratio of 11176.21 and a price-to-book ratio of 9.73 trading at moderately above to book value. The P/FCF stands at -28.38, also below market averages.